Downing Gregory J
Personalized Health Care Initiative, Office of the Secretary, Department of Health and Human Services, Hubert H. Humphrey Building, Suite 445F.5, 200 Independence Avenue, SW, Washington, DC 20201, USA.
Dialogues Clin Neurosci. 2009;11(4):377-87. doi: 10.31887/DCNS.2009.11.4/gjdowning.
Remarkable advances in the fundamental knowledge about the biological basis of disease and technical advances in methods to assess genomic information have led the health care system to the threshold of personalized medicine. It is now feasible to consider strategic application of genomic information to guide patient management by being predictive, preemptive, and preventive, and enabling patient participation in medical decisions. Early evidence of this transition has some hallmarks of disruptive innovation to existing health care practices. Presented here is an examination of the changes underway to enable this new concept in health care in the United States, to improve precision and quality of care through innovations aimed at individualized approaches to medical decision making. A broad range of public policy positions will need to be considered for the health care delivery enterprise to accommodate the promise of this new science and technology for the benefit of patients.
在疾病生物学基础的基础知识方面取得的显著进展以及评估基因组信息方法的技术进步,已将医疗保健系统带到了个性化医疗的门槛。现在,通过具有预测性、预防性和先发制人的能力,并让患者参与医疗决策,考虑基因组信息的战略应用以指导患者管理是可行的。这种转变的早期证据具有一些对现有医疗保健实践进行颠覆性创新的特征。本文探讨了美国正在进行的变革,以在医疗保健中实现这一新概念,通过旨在实现个性化医疗决策方法的创新来提高医疗的精准度和质量。为了使医疗保健服务企业能够利用这一新技术为患者带来的益处,需要考虑广泛的公共政策立场。